SEC Form 4 · accession 0001209191-18-038045
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asaf Danziger
Officer — Chief Executive Officer · Director
Period of report
Jun 13, 2018
Accepted (ET)
Jun 15, 2018 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 13, 2018 | S | 11,720 | $32.00 | D | 171,100 | D | |
| Ordinary SharesF1 | Jun 14, 2018 | S | 200 | $32.00 | D | 170,900 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.